Medplus Health Services Approves Audited Results, AGM on August 17, 2026
Medplus Health Services' board approved audited financial results for the year ended March 31, 2026, with revenue from operations at ₹18,643.85 million and PAT of ₹639.73 million. Ajit Pandurang Rangnekar and Mohankrishna Reddy Arvabumi were appointed as Additional Non-Executive Independent Directors effective May 20, 2026. Gangadi Madhukar Reddy was re-appointed as Managing Director from August 03, 2026. The 20th AGM is scheduled for August 17, 2026.
The announcement includes key board appointments and financial results, which are likely to have a moderate impact on the company's operations and investor perception.
The announcement includes both positive elements like financial results and appointments, and neutral elements like board meeting outcomes and resignations, balancing the overall sentiment.
MedPlus Health Services Limited's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The statutory auditors, M/s B S R and Co., Chartered Accountants, expressed an unmodified opinion in their report. The board also approved the allotment of 82,419 equity shares under the MedPlus Employees Stock Option Plan 2021 to eligible employees, increasing the paid-up equity share capital to ₹24,02,74,122.
The Board has approved convening the 20th Annual General Meeting (AGM) on Monday, August 17, 2026, via video conferencing. There were key management changes: Mr. Madhavan Ganesan and Mr. Murali Sivaraman's tenure as Non-Executive Independent Directors will end on June 10, 2026. Mr. Ajit Pandurang Rangnekar and Mr. Mohankrishna Reddy Arvabumi were appointed as Additional Non-Executive Independent Directors from May 20, 2026, for a five-year term, subject to shareholder approval. Mr. Gangadi Madhukar Reddy was re-appointed as Managing Director for five years starting August 03, 2026, pending member approval. Mr. Manoj Kumar Srivastava resigned as Company Secretary and Compliance Officer. M/s M P R & Associates were re-appointed as Cost Auditor for FY 2026-27.
For the quarter ended March 31, 2026, MedPlus reported revenue from operations of ₹18,643.85 million and a profit after tax of ₹639.73 million. The Board meeting, which commenced at 02:00 PM, concluded at 06:30 PM.
What to do with a filing like this
Medplus Health Services Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Medplus Health Services Limited. Read the original for the full detail.